^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

aDC1 vaccine

i
Other names: aDC1 vaccine, alphaDC1, alpha-type-1 polarized dendritic cells, autologous alpha-DC1/TBVA vaccine, αDC1-TBVA vaccine
Associations
Company:
Roswell Park, University of Pittsburgh
Drug class:
Immunostimulant
Related drugs:
Associations
3ms
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
P1/2, N=25, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
Enrollment open • Metastases
|
IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL3 (C-C Motif Chemokine Ligand 3) • ITGAX (Integrin Subunit Alpha X)
|
cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
3ms
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
4ms
Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy. (PubMed, J Immunol Res)
Alpha-type-1-polarized dendritic cells (aDC1s) have been shown to induce type-1 immunity with a high capacity to produce interleukin-12p70 (IL-12p70)...Cellular morphology was observed by electron microscopy, and the production of IL-12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8 hr of incubation at 4 or 22°C.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CSF2 (Colony stimulating factor 2) • IFNA1 (Interferon Alpha 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
|
aDC1 vaccine
5ms
Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
P2, N=42, Recruiting, Jodi Maranchie | Phase classification: P2a --> P2
Phase classification • Combination therapy
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP3 (Lysosomal Associated Membrane Protein 3) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • CD31 (Platelet and endothelial cell adhesion molecule 1) • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • ANXA5 (Annexin A5)
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
6ms
Trial completion date • Combination therapy • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
7ms
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
10ms
Enrollment open
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
11ms
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2025 --> Jan 2026
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
12ms
Enrollment change • Trial withdrawal • Immune cell
|
CD8 (cluster of differentiation 8)
|
aDC1 vaccine
1year
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P1/2, N=18, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Immune cell
|
CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1)
|
aDC1 vaccine
1year
Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression. (PubMed, Front Immunol)
Our pre-clinical data demonstrate the αDC1 vaccine's ability to induce anti-tumor effects by facilitating cytotoxic T lymphocyte activity and ablating the tumor vasculature. This work, overall, provides a foundation to further interrogate immune-mediated mechanisms of protection in order to help devise efficacious αDC1-based strategies for patients with CRC.
Journal
|
DLK1 (Delta Like Non-Canonical Notch Ligand 1)
|
DLK1 expression
|
aDC1 vaccine
over1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
over1year
Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
P2a, N=42, Recruiting, Jodi Maranchie | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • HES1 (Hes Family BHLH Transcription Factor 1) • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
over1year
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer. (ASCO 2023)
Exploratory endpoints include changes in intratumoral biomarkers (CTLs, PDL1, chemokines) in pre- and post-treatment peripheral tumor biopsies and immune changes in the blood. Clinical trial information: NCT04348747.
Clinical • P2a data • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCR5 (C-C Motif Chemokine Receptor 5) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
HER-2 overexpression • ERBB3 overexpression • CCR5 expression
|
Keytruda (pembrolizumab) • aDC1 vaccine
over1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> May 2025
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
over1year
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2024 --> Apr 2025
Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
almost2years
Enrollment change • Trial withdrawal
|
IFNG (Interferon, gamma)
|
aDC1 vaccine
almost2years
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P1/2, N=18, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Immune cell
|
CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1)
|
aDC1 vaccine
almost2years
Trial completion date • Metastases
|
IFNG (Interferon, gamma)
|
gemcitabine • aDC1 vaccine
almost2years
Phase classification • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine
2years
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (clinicaltrials.gov)
P1/2, N=25, Suspended, Roswell Park Cancer Institute | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
2years
New P1/2 trial • New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • aDC1 vaccine